» Articles » PMID: 31283601

Prognostic Value of Maximum Standardized Uptake Value in 68Ga-Somatostatin Receptor Positron Emission Tomography for Neuroendocrine Tumors: A Systematic Review and Meta-analysis

Overview
Journal Clin Nucl Med
Specialty Nuclear Medicine
Date 2019 Jul 9
PMID 31283601
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Somatostatin receptor (SSTR) PET has become a mainstay in the diagnosis of neuroendocrine tumors (NETs) and for selecting patients for SSTR-based therapy; however, no consensus has yet been reached in terms of prognosis. A systematic review and meta-analysis was performed on the prognostic value of the maximum standardized uptake value (SUVmax) for Ga-SSTR PET in patients with NETs.

Patients And Methods: We performed a systematic search using the following keywords: PET, SSTR, NET, and prognosis. The inclusion criteria were the use of Ga-SSTR PET as an imaging tool, studies limited to NETs, studies that reported progression-free survival (PFS) and/or overall survival (OS), and studies that included SUVmax as a prognostic parameter. The effect of SUVmax on PFS and OS was measured in terms of the hazard ratio (HR).

Results: Eight eligible studies with 474 patients were finally included and analyzed. The combined HR of SUVmax on PFS was 2.31 with significance (95% confidence interval [CI], 1.34-4.00; P = 0.003). The trim and fill adjusted analysis for SUVmax on PFS demonstrated the combined HR as 1.81 with significance (95% CI, 1.11-2.95; P = 0.017), as the publication bias was found (Egger P = 0.004). The combined HR of SUVmax on OS was 2.97 with significance (95% CI, 1.71-5.15; P = 0.0001), without publication bias (Egger P = 0.929). The subgroup analysis revealed that well-differentiated NETs (grade 1 or 2) on PFS showed significance (P = 0.03); however, all grades of NETs (including grade 3) on PFS did not reach significance (P = 0.11). Tumor site and type of radiotracer did not affect the prognostic value of SUVmax.

Conclusions: Low SUVmax of Ga-SSTR PET was associated with a worse prognosis for PFS and OS in patients with NETs. Well-differentiated NETs had more prognostic value compared with all grades of NETs. The SUVmax of Ga-SSTR PET could be used as an objective prognosis predictor.

Citing Articles

Synchronous neuroendocine liver metastases in comparison to primary pancreatic neuroendocrine tumors on MRI and SSR-PET/CT.

Horng A, Ingenerf M, Berger F, Steffinger D, Rubenthaler J, Zacherl M Front Oncol. 2024; 14:1352538.

PMID: 38884077 PMC: 11179428. DOI: 10.3389/fonc.2024.1352538.


Outcome prediction of SSTR-RADS-3A and SSTR-RADS-3B lesions in patients with neuroendocrine tumors based on Ga-DOTATATE PET/MR.

Gao J, Zhou J, Liu C, Pan Y, Lin X, Zhang Y J Cancer Res Clin Oncol. 2024; 150(5):272.

PMID: 38795250 PMC: 11127844. DOI: 10.1007/s00432-024-05776-5.


Prognostic Implications of PET-Derived Tumor Volume and Uptake in Patients with Neuroendocrine Tumors.

Weber M, Telli T, Kersting D, Seifert R Cancers (Basel). 2023; 15(14).

PMID: 37509242 PMC: 10377105. DOI: 10.3390/cancers15143581.


Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary Gastroenteropancreatic Neuroendocrine Tumors.

Gallicchio R, Giordano A, Milella M, Storto R, Pellegrino T, Nardelli A Cancer Control. 2023; 30:10732748231152328.

PMID: 36714951 PMC: 9940184. DOI: 10.1177/10732748231152328.


Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [Cu]Cu-DOTA-TOC.

Vahidfar N, Farzanehfar S, Abbasi M, Mirzaei S, Delpassand E, Abbaspour F Cancers (Basel). 2022; 14(8).

PMID: 35454822 PMC: 9027354. DOI: 10.3390/cancers14081914.